BridgeBio Pharma (BBIO) Change in Acquisitions & Divestments (2020 - 2026)

BridgeBio Pharma has reported Change in Acquisitions & Divestments for 6 years, with the latest figure at $10.0 million in Q1 2026.

• Quarterly Change in Acquisitions & Divestments changed N/A year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 68.52% YoY) and the FY2024 annual result came in at $95.0 million, down 14.07% from the prior year.
• Change in Acquisitions & Divestments declined to $10.0 million in Q1 2026 per BBIO's latest filing, from $31.8 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $443.1 million in Q3 2022 and troughed at $3.0 million in Q2 2022.
• A 4-year average of $63.2 million and a median of $26.9 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments slumped 97.83% in 2022, then jumped 675.44% in 2023.
• Over 4 years, Change in Acquisitions & Divestments stood at $26.9 million in 2022, then climbed by 10.14% to $29.6 million in 2023, then rose by 7.36% to $31.8 million in 2024, then tumbled by 68.52% to $10.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $10.0 million, $31.8 million, and $63.2 million for Q1 2026, Q4 2024, and Q1 2024 respectively.